Influenza A, COVID-19 and norovirus (stomach flu) are on the rise, according to the Centers for Disease Control and Prevention. But there's a fourth "bug" the public should be aware of: respiratory syncytial virus. RSV causes cold-like symptoms and affects the breathing passages and lungs.

State Public Health Data shows flu and RSV hospitalizations are rising. Officials say this season is similar to pre-COVID years.

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC continued to monitor for GBS risk. FDA conducted a postmarket

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.